Ukuxhatshazwa phakathi kokudliwa kwesidlo kunye nokuphazamiseka kokusetyenziswa kweziyobisi: Ukuxilonga kunye neurobiology (2013)

U-Ait-Daoud, N., Roache, JD, Dawes, MA, Liu, L., Wang, XQ., Javors, MA, Seneviratne, C. & Johnson, BA (2009): Ngaba i-serotonin transporter genotype ixela kwangaphambili ukulangazelela utywala? UPhando loMfuniselo lweKlinikhi yoTywala, i-33(8), 1329-1335.

U-Alger, SA, Schwalberg, MD, Bigaouette, JM, Michalek, AV & Howard, LJ (1991): Impembelelo ye-tricyclic antidepressant kunye ne-opiate antagonist ekuziphatheni kokutya kwi-normo-weight bulimic kunye ne-obese, izifundo ezidliwayo. Ijenali yaseMelika yeZondlo zeklinikhi, i53(4), 865-871.

Umbutho waseMelika weeNgqondo (2013): Inkcazo yokuxilonga kunye neenkcukacha zeengxaki zengqondo (uhlelo lwesi-5). Arlington, VA: Umbhali.

UAnderson, JW, Greenway, FL, Fuijoka, K., Gadde, KM, McKenney, J. & O'Neil, PM (2002): I-Bupropion SR iphucula ukulahleka kwesisindo: I-28-iveki ephindwe kabini, isilingo esilawulwa yi-placebo. Uphando lokutyeba, i-10(7), 633-641.

Arbaizar, B., Dierssen-Sotos, T., Gómez-Acebo, I. & Llorca J. (2010): I-Topiramate kunyango lokuxhomekeka kotywala: Uhlalutyo lwe-meta. Actas Españolas de Psiquiatria, 38, 8-12.

U-Asin, KE, Davis, JD & Bednarz, L. (1992): Imiphumo eyahlukileyo yeziyobisi ze-serotonergic kunye ne-catecholaminergic ekuziphatheni kokutya. Psychopharmocology (Berlin), 109, 415-421.

I-Avena, i-NM, i-Rada, i-P. & ne-Hoebel, i-BG (i-2008): Ubungqina bokuxilwa kweswekile: Imiphumo yokuziphatha kunye ne-neurochemical ye-intermittent, i-sugar intake. Uphononongo lwe-Neuroscience Biobehavioral, i-31, 20-39.

I-Avena, i-NM, i-Rada, i-P. & no-Hoebel, i-BG (2009): Iswekile kunye ne-fat binging inomahluko ophawulekayo ekuziphatheni okufana nokulutha. Ijenali yeZondlo, i-139(3), 623-628.

Baker, DA, McFarland, K., Lake, RW, Shen, H., Tang, XC, Toda, S. & Kalivas, PW (2003): I-Neuroadaptations kwi-cystine-glutamate exchange underlie cocaine relapse. I-Neuroscience, 6, 743-749.

Balodis, IM, Molina, ND, Kober, H., Worhunsky, PD, White, MA, Sinha, R., Grilo, CM & Potenza, MN (2013): I-neural substrates ezihlukeneyo zokulawula inhibitory ekutyeni ukuphazamiseka kokutya ngokumalunga nezinye ukubonakaliswa kokutyeba. Ukutyeba, 21(2), 367-377.

U-Brody, AL, Mandelkern, MA, Lee, G., Smith, E., Sadeghi, M., Saxena, S., Jarvik, ME & London, ED (2004): Ukunciphisa i-cue-included cigarette craving and anterior cingulate cortex ukusebenza kwi-bupropion ephathwayo ababhemayo: isifundo sokuqala. UPhando lwezeMpilo yeNgqondo, i130, 269-281.

I-Bulik, CM, Sullivan, PF & Kendler, KS (2002): Ukugula kwezonyango kunye nengqondo kubasetyhini abatyebileyo kunye nangaphandle kokutya. Ijenali yeHlabathi yeZiphazamiso zokutya, i-32(1), 72-78.

Cambridge, VC, Ziauddeen, H., Nathan, PJ, Subramaniam, N., Dodds, C., Chamberlain, SR, Koch, A., Maltby, K., Skeggs, AL, Napolitano, A., Farooqi, IS, I-Bullmore, i-ET & Fletcher, i-PC (i-2013): Iziphumo ze-Neural kunye nokuziphatha kwenoveli ye-opioid receptor antagonist ekutya ngokugqithisileyo abantu abatyebileyo. Ingqondo yebhayiloji ye-Biological, 73, 887-894.

UCassin, SE & von Ranson, KM (2007): Ngaba ukuzinkcinkca ngokutya kunamava njengomlutha? Umnqweno wokutya, i-49(3), 687-690.

Chamberlain, SR, Mogg, K., Bradley, BP, Koch, A., Dodds, CM, Tao, WX, Maltby, K., Sarai, B., Napolitano, A., Richards, DB, Bullmore, ET & Nathan , PJ (2012): Iziphumo ze-opioid receptor antagonism kwi-cognition kubantu abatyebileyo abatyebileyo. Psychopharmacology (Berlin), 224(4), 501-509.

UClaudino, AM, de Oliveira, IR, Appolinario, JC, Cordás, TA, Duchesne, M., Sichieri, R. & Bacaltchuk, J. (2007): Uvavanyo oluphindwe kabini oluyimfama, olungahleliwe, olulawulwa yi-placebo lwe-topiramate kunye nokuziphatha kwengqondo unyango kwingxaki yokutya ngokugqithisileyo. Ijenali yeClinical Psychiatry, 68, 1324-1332.

I-Corsica, JA & Spring, BJ (2008): Umnqweno weCarbohydrate: Uvavanyo oluphindwe kabini oluyimfama, olulawulwa yi-placebo lwe-self-medication hypothesis. Ukuziphatha kokutya, 9, 447-454.

ICottone, P., Sabino, V., Steardo, L. & Zorrilla, EP (2008): Ukuxhomekeka kwe-opioid elindelekileyo ngokuchaseneyo kunye nokutya okufana nokutya kwiigundane kunye nokufikelela okulinganiselweyo kokutya okuthandwa kakhulu. I-Neuropsychopharmacology, 33, 524-535.

UDavis, C. & Carter, JC (2009): Ukutya okunyanzelekileyo njengengxaki yokulutha: Uphononongo lwethiyori kunye nobungqina. Umnqweno wokutya, i-53, 1-8.

UDavis, C., Curtis, C., Levitan, RD, Carter, JC, Kaplan, AS & Kennedy, JL (2011): Ubungqina bokuba 'umlutha wokutya' yi-phenotype esebenzayo yokukhuluphala. Umnqweno wokutya, i-57, 711-717.

UDavis, CA, Levitan, RD, Reid, C., Carter, JC, Kaplan, AS, Patte, KA, King, N., Curtis, C. & Kennedy, JL (2009): I-Dopamine "yokufuna" kunye ne-opioids “Ukuthanda”: ​​Uthelekiso lwabantu abadala abatyebe ngokugqithiseleyo nabangazityiyo. Ukutyeba, 17, 1220-1225.

I-Dingemans, i-AE, i-Bruna, i-MJ & van Furth, i-EF (2002): Ukuphazamiseka kokutya ngokutya: Uphononongo. Ijenali ye-Obesity Related Metabolism Disorders, i-26, 299-307.

I-Drewnowski, A., Krahn, DD, Demitrack, MA, Nairn, K. & Gosnell, BA (1995): I-Naloxone, i-opiate blocker, iyanciphisa ukusetyenziswa kokutya okunamafutha aphezulu kwi-obese kunye nabatyebileyo ababhinqileyo abadla ngokutya. Ijenali yaseMelika yeZondlo zeklinikhi, i61, 1206-1212.

UFerriter, C. & Ray, LA (2011): Ukutya ngokutya kunye nokusela utywala: Uphononongo oludibeneyo. Ukuziphatha kokutya, 12, 99-107.

Fortuna, JL (2012): Ubhubhani wokutyeba kunye nokongezwa kokutya: Ukufana kweklinikhi nokuxhomekeka kweziyobisi. Ijenali yeziyobisi zePsychoactive, 44(1), 56-63.

UGadalla, T. & Piran, N. (2007): I-Co-occurrence yokuphazamiseka kokutya kunye nokuphazamiseka kokusetyenziswa kotywala kwabasetyhini: Uhlalutyo lwemeta. Oovimba beMpilo yeNgqondo yabaseTyhini, 10, 133-140.

UGadde, KM, Parker, CB, Maner, LG, Wagner, HR, 2nd, Logue, EJ, Drezner, MK & Krishnan, KR (2001): I-Bupropion yokulahlekelwa kwesisindo: Uphando olusebenzayo kunye nokunyamezela kubafazi abakhulu kunye nabakhulupheleyo. Uphando lokutyeba, i-9(9), 544-551.

Garbutt, JC, West, SL, Carey, TS, Lohr, KN & Crews, FT (1999): Unyango lwe-Pharmacological yokuxhomekeka kotywala. Ijenali yeAmerican Medical Association, 281, 1318-1325.

Gearhardt, AN, Corbin, WR & Brownell, KD (2009): Ukuqinisekiswa kwangaphambili kweYale Food Addiction Scale. Umnqweno wokutya, i-62, 430-436.

Gearhardt, AN, White, MA & Potenza, MN (2011): Ukuphazamiseka kokutya kunye nokulutha kokutya. Uphononongo lwangoku lokuSetyenziswa kweZiyobisi, 4, 201-207.

Grant, JE, Potenza, MN, Weinstein, A. & Gorelick, DA (2010): Intshayelelo kwiziyobisi zokuziphatha. Ijenali yaseMelika yokuSetyenziswa gwenxa kweziyobisi kunye noTywala, 36, 233-241.

Greenway, FL, Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K. & Cowley, MA (2009): Ukuthelekiswa konyango oludibeneyo lwe-bupropion kunye ne-naltrexone yokutyeba nge-monotherpay kunye ne-placebo. Ijenali yeClinical Endocrinology kunye neMetabolism, i-94(12), 4898-4906.

I-Grilo, i-CM, i-White, i-MA kunye ne-Masheb, i-RM (2009): i-DSM-IV yengqondo yokuphazamiseka kwengqondo kunye ne-correlates kwi-disorder yokutya. Ijenali yeHlabathi yeZiphazamiso zokutya, i-42, 228-234.

I-Haltia, LT, Rinne, JO, Merisaari, H., Maguire, RP, Savontaus, E., Helin, S., Någren, K. & Kaasinen, V. (2007): Imiphumo ye-glucose ye-intravenous kumsebenzi we-dopaminergic kumntu ingqondo kwi vivo. USinapse, 61(9), 748-756.

Hommer, RE, Seo, D., Lacadie, CM, Chaplin, TM, Mayes, LC, Sinha, R. & Potenza, MN (2012): I-Neural correlates yoxinzelelo kunye nokuvezwa kokutya okuthandayo kulutsha: I-resonance magnetic esebenzayo isifundo somfanekiso. Imephu yoBuchule boMntu, i-Epub ngaphambi kokuprintwa, doi: 10.1007/s11947-011-0773-6

Hudson, JI, McElroy, SL, Raymond, NC, Crow, S., Keck, PE, Jr., Carter, WP, Mitchell, JE, Strakowski, SM, Pope, HG, Jr., Coleman, BS & Jonas, JM (1998): I-Fluvoxamine kunyango lwe-binge-eating disorder: Ulingo olulawulwa yi-placebo oluninzi. I-American Journal of Psychiatry, i-155, 1756-1762.

Ifland, JR, Preuss, HG, Marcus, MT, Rourke, KM, Taylor, WC, Burau, K., Jacobs, WS, Kadish, W. & Manso, G. (2009): Likhoboka lokutya okucokisekileyo: Ukusetyenziswa kweziyobisi zakudala ukuphazamiseka. Iingcamango zonyango, i-72, 518-526.

Jain, AK, Kaplan, RA, Gadde, KM, Wadden, TA, Allison, DB, Brewer, ER, Leadbetter, RA, Richard, N., Haight, B., Jamerson, BD, Buaron, KS & Metz, A. (2002): I-Bupropion SR vs i-placebo yokulahlekelwa kwesisindo kwizigulane ezityebileyo ezineempawu zokudakumba. Uphando lokutyeba, i-10, 1049-1056.

UJohnson, PM & Kenny, PJ (2010): I-Dopamine D2 receptors kwi-addiction-efana nokungasebenzi komvuzo kunye nokutya okunyanzelekileyo kwiigundane ezityebileyo. Inzululwazi yezendalo, i-13, 635-641.

Jorenby, DE, Leischow, SJ, Nides, MA, Rennard, SI, Johnston, JA, Hughes, AR Smith, SS, Muramoto, ML, Daughton, DM, Doan, K., Fiore, MC & Baker, TB (1999) : Ulingo olulawulwayo lwe-bupropion ekhutshiweyo ezinzileyo, i-nicotine patch, okanye zombini zokuyeka ukutshaya. INew England Journal of Medicine, 340, 685-691.

Kessler, RC, Berglund, PA, Chiu, WT, Deitz, AC, Hudson, JI, Shahly, V., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, MC, Benjet, C., Bruffaerts, R. , de Girolamo, G., de Graaf, R., Maria Haro, J., Kovess-Masfety, V., O'Neill, S., Posada-Villa, J., Sasu, C., Scott, K., Viana, MC & Xavier, M. (2013): Ukuxhaphaka kunye nokulungelelaniswa kokuphazamiseka kokutya kwi-World Health Organization World Mental Health Surveys. Ingqondo yebhayiloji ye-Biological, 73, 904-914.

UKumkani, AC, Cao, D., Zhang, L. & O'Malley, SS (2013): Ukunciphisa i-Naltrexone yokunciphisa ukutshaya kwexesha elide lokufumana ubunzima kubasetyhini kodwa kungekhona amadoda: Ulingo olulawulwa ngokungahleliwe. Ingqondo yebhayiloji ye-Biological, 73, 924-930.

Koob, GF & Le Moal, M. (2001): Ukuxhatshazwa kweziyobisi, ukuxhatshazwa komvuzo, kunye ne-allostatis. I-Neuropsychopharmacology, 24, 97-129.

Lewinsohn, PM, Seeley, JR, Moerk, KC & Striegel-Moore, RH (2002): Ukwahlukana ngokwesini kwiimpawu zokuphazamiseka kokutya kubantu abadala abaselula. Ijenali yaMazwe ngaMazwe yokuPhazamiseka kokuTya, i-32, 426-440.

Lilenfeld, LRR, Ringham, R., Kalarchian, MA & Marcus, MD (2008): Uphando lwembali yentsapho yokuphazamiseka kokutya. Ingqondo ebanzi yoNyango, i-49, 247-254.

Luce, KH, Engler, PA & Crowther, JH (2007): Ukuphazamiseka kokutya kunye nokusetyenziswa kotywala: Ukwahlukana kweqela kumazinga okusetyenziswa kunye neenjongo zokusela. Ukuziphatha kokutya, 8, 177-184.

UMaldonado-Irizarry, CS, Swanson, CJ & Kelley, AE (1995): I-Glutamate receptors kwi-nucleus accumbens igobolondo lokulawula ukuziphatha kokutya nge-hypothalamus esecaleni. I-Journal ye-Neuroscience, i-15, 6779-6788.

Marrazzi, MA, Markham, KM, Kinzie, J. & Luby, ED (1995): Ukuphazamiseka kokutya ngokutya: Ukuphendula kwi-naltrexone. Ijenali yeZizwe ngezizwe yokuObesity kunye ne-Related Metabolism Disorders, i-19(2), 143-145.

McElroy, SL, Arnold, LM, Shapira, NA, Keck, PE, Jr., Rosenthal, NR, Karim, MR, Kamin, M. & Hudson, JI (2003): I-Topiramate kunyango lokutya ukutya okuninzi okuhambelana nokukhuluphala : Ulingo olungenamkhethe, olulawulwa yi-placebo. I-American Journal of Psychiatry, i-160, 255-261.

McElroy, SL, Casuto, LS, Nelson, EB, Lake, KA, Soutullo, CA, Keck, PE, Jr. & Hudson, JI (2000): Uvavanyo olulawulwa yi-placebo lwe-sertraline kunyango lokutya ukutya. I-American Journal of Psychiatry, i-157, 1004-1006.

UMcElroy, SL, Guerdjikova, AI, Mori, N. & O'Melia, AM (2012): Ulawulo lwe-Pharmacological of binge food disorder: Iinketho zonyango ezikhoyo kunye nezikhulayo. Unyango kunye noLawulo lweNgozi yoNyango, i-8, 219-241.

McElroy, SL, Guerdjikova, AI, Winstanley, EL, O'Melia, AM, Mori, N., McCoy, J., Keck, PE & Hudson, JI (2011): I-Acamprosate kunyango lwe-disorder yokutya: I-placebo -ulingo olulawulwayo. Ijenali yeHlabathi yeZiphazamiso zokutya, i-44, 81-90.

McElroy, SL, Hudson, JI, Capece, JA, Beyers, K., Fisher, AC, Rosenthal, NR & Topiramate Binge Eating Disorder Research Group (2007): I-Topiramate yonyango lokuphazamiseka kokutya okuhambelana nokutyeba: I-placebo- isifundo esilawulwayo. Ingqondo yebhayiloji ye-Biological, 61, 1039-1048.

Merikangas, KR & McClair, VL (2012): I-Epidemiology yokuphazamiseka kokusetyenziswa kweziyobisi. Imfuzo yabantu, i-131, 779-789.

Meyer, F. (2008): Ukunciphisa kokubini kokutya kunye nokungasebenzi kakuhle ngokwesondo kunye ne-naltrexone. Ijenali yeClinikhi Psychopharmacology, 28(6), 722-723.

Miller, PM, Book, SW & Stewart, SH (2011): Unyango lonyango lokuxhomekeka kotywala: Ukuphononongwa ngokuchanekileyo. Ijenali yeHlabathi ye-Psychiatry Medicine, i-42(3), 227-266.

Myers, KM, Carlezon, WA, Jr. & Davis, M. (2011): I-Glutamate receptors kwi-extinction kunye ne-extinction-based based treatments for disease disorder. I-Neuropsychopharmacology, 36, 274-293.

I-Neumeister, A., Winkler, A. & Wober-Bingol, C. (1999): Ukongezwa kwe-naltrexone kwi-fluoxetine kunyango lokutya ukutya. I-American Journal of Psychiatry, i-156(5), 797.

Rabiner, EA, Beaver, J., Makwana, A., Searle, G., Long C., Nathan, PJ, Newbould, RD, Howard, J., Miller, SR, Bush, MA, Hill, S., Reiley , R., Passchier, J., Gunn, RN, Matthews, PM & Bullmore, ET (2011): Ukwahlukana kwe-Pharmacological ye-opioid receptor antagonists nge-molecular and functional imaging yendawo ekujoliswe kuyo kunye nokutya okunxulumene nokusebenza kwengqondo ebantwini. I-Molecular Psychiatry, i-16, 826-835.

Schaechter, JD & Wurtman, RJ (1990): Ukukhululwa kweSerotonin kuyahluka kunye namanqanaba e-tryptophan yengqondo. Uphando lweBongo, 532, 203-210.

I-Sheng, i-LX, i-Tang, i-YL, i-Jiang, i-ZN, i-Yao, i-CH, i-Gao, i-JY, i-Xu, i-GZ & ne-Tong, i-XY (i-2013): i-bupropion eqhubekayo yokuyeka ukutshaya kwisampuli yaseTshayina: I-double-blind, i-placebo elawulwayo , uvavanyo olungenamkhethe. Inikotini kunye noPhando lweCuba, i-15(2), 320-325.

Sim, LA, McAlpine, DE, Grothe, KB, Himes, SM, Cockerill, RG & Clark, MM (2010): Ukuchongwa kunye nokunyangwa kweengxaki zokutya kwindawo yokunyamekela okuphambili. IiNkqubo zeKlinikhi yaseMayo, i-85, 746-751.

USmith, DG & Robbins, TW (2013): I-neurobiological under-pinnings yokutyeba kunye nokutya kakhulu: Ingqiqo yokwamkela imodeli yokutya. Ingqondo yebhayiloji ye-Biological, 72(9), 804-810.

I-Snyder, JL & Bowers, TG (2008): Ukusebenza kwe-acamprosate kunye ne-naltrexone kunyango lokuxhomekeka kotywala: Uhlalutyo lweenzuzo ezinxulumene nezilingo ezilawulwa ngokungahleliwe. Ijenali yaseMelika yokuSetyenziswa gwenxa kweziyobisi kunye noTywala, 34, 449-461.

Spring, B., Wurtman, J., Gleason, R. & Kessler, K. (1991): Ukuzuza ubunzima kunye neempawu zokuhoxiswa emva kokuyeka ukutshaya: Ukungenelela kokuthintela usebenzisa i-d-fenfluramine. ISakholoji yezeMpilo, i-10, 216-223.

ITanofsky-Kraff, M., Bulik, CM, Marcus, MD, Striegel, RH, Wilfley, DE, Wonderlich, SA & Hudson, JI (2013): Ukuphazamiseka kokutya ngokutya: Isizukulwana esilandelayo sophando. Ijenali yeHlabathi yeZiphazamiso zokutya, i-46, 193-207.

UTata, AL & Kockler, DR (2006): I-Topiramate yokuphazamiseka kokutya okunxulumene nokukhuluphala. Iingxelo ze-Pharmaco-therapy, 40(11), 1993-1997.

Thanos, PK, Bermeo, C., Wang GJ & Volkow, ND (2011): I-Bromocriptine yanda i-opharenti ephendula ngokutya okunamafutha aphezulu kodwa iyancipha i-chow intake kuzo zombini iigundane ezityebileyo kunye nezixhathisayo. UPhando loBuchule bokuziphatha, i-217, 165-170.

van den Brink, W. (2012): Ubungqina obusekelwe kunyango lwe-pharmacological yokuphazamiseka kokusetyenziswa kweziyobisi kunye nokungcakaza kwe-pathological. Uphononongo lwangoku lokuSetyenziswa kweZiyobisi, 5, 3-31.

Volkow, ND, Wang, GJ, Telang, F., Fowler, JS, Thanos, PK, Logan, J., Alexoff, D., Ding, YS, Wong, C., Ma, Y. & Pradhan, K. ( 2008): I-dopamine striatal receptors ephantsi ye-D2 receptors inxulunyaniswa ne-prefrontalmetabolism kwizifundo ezityebileyo: Izinto ezinokuba negalelo. I-Neuroimage, i-42(4), 1537-1543.

I-Volkow, ND, Wang, GJ, Tomasi, D. & Baler, RD (2013): Ukutyeba kakhulu kunye nokulutha: I-Neurobiological overlaps. Uphononongo lokutyeba, 14, 2-18.

Wang, GJ, Geliebter, A., Volkow, ND, Telang, FW, Logan, J., Jayne, MC, Galanti, K., Selig, PA, Han, H., Zhu, W., Wong, CT & Fowler , JS (2011): Ukomelezwa kwe-striatal dopamine ekhutshwe ngexesha lokuvuselela ukutya kukuphazamiseka kokutya. Ukutyeba, 19, 1601-1608.

Wang, GJ, Volkow, ND, Logan, J., Pappas, NR, Wong, CT, Zhu, W., Netusil, N. & Fowler, JS (2001): Ubuchopho be-dopamine kunye nokukhuluphala. ILancet, 357, 354-357.

Wang, GJ, Volkow, ND, Thanos, PK & Fowler, JS (2004): Ukufana phakathi kokukhuluphala kunye nokulutha kweziyobisi njengoko kuhlolwe yi-neurofunctional imagining: Ukuhlaziywa kwengcamango. Ijenali ye-Addictive Disorders, i-23, 39-53.

I-White, i-MA kunye ne-Grilo, i-CM (i-2013): I-Bupropion yabasetyhini abatyebileyo abane-disorder-disorder disorder: Uvavanyo olungahleliwe, oluyimfama oluphindwe kabini, olulawulwa yi-placebo. Ijenali yeClinical Psychiatry, i-74(4), 400-406.

Isilumko, i-RA (2004): Imivuzo efunwayo: Iindlela ze-Molecular of motivation. I-Discovery Medicine, i-4, 180-186.

UZhang, M., Gosnell, BA & Kelley, AE (1998): Ukungeniswa kokutya okunamafutha aphezulu kunyuswa ngokukhethiweyo yi-mu opioid receptor stimulation ngaphakathi kwe-nucleus accumbens. Ijenali ye-Pharmacology kunye ne-Experimental Therapeutics, i-285, 908-914.

UZiauddeen, H., Farooqi, IS & Fletcher, PC (2012): Ukutyeba kakhulu kunye nengqondo: Iqinisekisa njani imodeli yokulutha. Uhlolo lweNdalo Neuroscience, 13, 279-286.

Ziauddeen, H. & Fletcher, PC (2012): Ngaba umlutha wokutya ngumbono osebenzayo kunye noluncedo? UPhononongo lwe-Obesity, i-14, 19-28.